MILAN--( BUSINESS WIRE )--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces very compelling new results from the first 100 enrolled patie
Full Story >>
Vote
+8